COMP <GO>
MYRG vs TMO // RETURN ON INVESTED CAPITAL (ROIC)
MYR Group Inc. (NASDAQ) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: MYRG 7
— TMO 7
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: MYRG
LAST: $282.62 (-0.13%) • MKT CAP: $4.41B
roic
23.30%
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
roic
9.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MYRG VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MYRG | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 11.60% | 41.00% | -29.40 | TMO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 23.30% | 9.30% | +14.00 | MYRG | /roic <GO> |
| EV/EBITDA & P/E Valuation | 17.4x | 30.4x | -13.00 | MYRG | /valuation <GO> |
| Free Cash Flow Yield | 5.27% | 2.40% | +2.87 | MYRG | /fcf-yield <GO> |
| Operating Margin | 4.60% | 17.40% | -12.80 | TMO | /operating-margins <GO> |
| Net Profit Margin | 3.20% | 15.10% | -11.90 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 8.80% | 3.90% | +4.90 | MYRG | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.24% | -0.24 | TMO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.87 | 4.50 | +1.37 | MYRG | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.70% | +0.20 | TMO | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.4 | 59.1 | -10.80 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.01 | 0.94 | +0.07 | MYRG | /macro-sensitivity <GO> |
| Forward P/E Multiple | 34.6x | 36.3x | -1.70 | MYRG | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.41B | $262.22B | -$257.81B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MYRG REV | TMO REV | MYRG GROSS % | TMO GROSS % | MYRG FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.66B | $44.56B | 11.6% | 44.0% | $232.2M | $6.29B |
| FY 2024 | $3.36B | $42.88B | 8.6% | 44.0% | $11.2M | $7.27B |
| FY 2023 | $3.64B | $42.86B | 44.0% | 44.0% | -$93.0M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MYRG // BETA 1.01
TMO // BETA 0.94